{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:44:44Z","timestamp":1793227484430,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["APP1176324"],"award-info":[{"award-number":["APP1176324"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["APP1117940"],"award-info":[{"award-number":["APP1117940"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["FSPGN000048"],"award-info":[{"award-number":["FSPGN000048"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cmi.2025.09.015","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:59:36Z","timestamp":1758949176000},"page":"110-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Complex pathways to ceftolozane-tazobactam resistance in clinical Pseudomonas aeruginosa isolates: a genomic epidemiology study"],"prefix":"10.1016","volume":"32","author":[{"given":"Hoai-An","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton Y.","family":"Peleg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangning","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Wisniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke V.","family":"Blakeway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gnei Z.","family":"Badoordeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravali","family":"Theegala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhu Quynh","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Dowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Macesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.09.015_bib1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.09.015_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2025.09.015_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","article-title":"Multidrug-resistant gram-negative bacterial infections","volume":"405","author":"Macesic","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.09.015_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.pathol.2023.03.009","article-title":"Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia","volume":"55","author":"Kostoulias","year":"2023","journal-title":"Pathology"},{"key":"10.1016\/j.cmi.2025.09.015_bib5","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.cmi.2021.05.011","article-title":"Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis","volume":"27","author":"Cortes-Lara","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.09.015_bib6","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.09.015_bib7","doi-asserted-by":"crossref","first-page":"e4599","DOI":"10.1093\/cid\/ciaa1306","article-title":"Modifiable risk factors for the emergence of ceftolozane-tazobactam resistance","volume":"73","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.015_bib8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.09.015_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlad080","article-title":"Susceptibility profile and \u03b2-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane\/tazobactam and\/or imipenem\/relebactam\u2014SMART 2016\u201321","volume":"5","author":"Karlowsky","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.09.015_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00084-21","article-title":"In Vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam","volume":"65","author":"Rubio","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.09.015_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01589-17","article-title":"Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain","volume":"61","author":"Del Barrio-Tofi\u00f1o","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.09.015_bib12","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/jac\/dkz147","article-title":"Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology","volume":"74","author":"del Barrio-Tofi\u00f1o","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.09.015_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.01026-20","article-title":"Ceftolozane\/tazobactam resistance and mechanisms in carbapenem-nonsusceptible Pseudomonas aeruginosa","volume":"6","author":"Teo","year":"2021","journal-title":"mSphere"},{"key":"10.1016\/j.cmi.2025.09.015_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00496-22","article-title":"Whole-genome sequencing reveals diversity of carbapenem-resistant Pseudomonas aeruginosa collected through CDC\u2019s emerging infections program, United States, 2016-2018","volume":"66","author":"Stanton","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.09.015_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100736","article-title":"Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis","volume":"34","author":"Sastre-Femenia","year":"2023","journal-title":"Lancet Regional Health\u2014Europe"},{"key":"10.1016\/j.cmi.2025.09.015_bib16","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0","year":"2023"},{"key":"10.1016\/j.cmi.2025.09.015_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005595","article-title":"Unicycler: resolving bacterial genome assemblies from short and long sequencing reads","volume":"13","author":"Wick","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.cmi.2025.09.015_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91456-0","article-title":"AMRFinderPlus and the reference gene catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence","volume":"11","author":"Feldgarden","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2025.09.015_bib19","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1093\/bioinformatics\/bty539","article-title":"Pyseer: a comprehensive tool for microbial pangenome-wide association studies","volume":"34","author":"Lees","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cmi.2025.09.015_bib20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat Methods"},{"key":"10.1016\/j.cmi.2025.09.015_bib21","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.cmi.2025.09.015_bib22","series-title":"The PyMOL molecular graphics system, version 1.8","author":"Schr\u00f6dinger","year":"2015"},{"key":"10.1016\/j.cmi.2025.09.015_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00785-24","article-title":"\u03b2-Lactamase diversity in Pseudomonas aeruginosa","volume":"69","author":"Mack","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.09.015_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/jac\/dkaa430","article-title":"Distinct epidemiology and resistance mechanisms affecting ceftolozane\/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS","volume":"76","author":"Hern\u00e1ndez-Garc\u00eda","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.09.015_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab311","article-title":"Cefiderocol activity against clinical Pseudomonas aeruginosa isolates exhibiting ceftolozane-tazobactam resistance","volume":"8","author":"Simner","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.015_bib26","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s10096-018-3361-0","article-title":"Ceftolozane\/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands","volume":"37","author":"D\u00edaz-Ca\u00f1estro","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.015_bib27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s42256-024-00795-w","article-title":"Protein function prediction as approximate semantic entailment","volume":"6","author":"Kulmanov","year":"2024","journal-title":"Nat Machine Intelligence"},{"key":"10.1016\/j.cmi.2025.09.015_bib28","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.1073\/pnas.83.19.7236","article-title":"An essential function for acyl carrier protein in the biosynthesis of membrane-derived oligosaccharides of Escherichia coli","volume":"83","author":"Therisod","year":"1986","journal-title":"Proc Nat Acad Sci"},{"key":"10.1016\/j.cmi.2025.09.015_bib29","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.3389\/fmicb.2018.02244","article-title":"Acyl carrier protein 3 is involved in oxidative stress response in Pseudomonas aeruginosa","volume":"9","author":"Chen","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2025.09.015_bib30","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1128\/AAC.02556-14","article-title":"The Pseudomonas aeruginosa CreBC two-component system plays a major role in the response to \u03b2-lactams, fitness, biofilm growth, and global regulation","volume":"58","author":"Zamorano","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.09.015_bib31","doi-asserted-by":"crossref","first-page":"D646","DOI":"10.1093\/nar\/gkv1227","article-title":"Enhanced annotations and features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database","volume":"44","author":"Winsor","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cmi.2025.09.015_bib32","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/femsre\/fuw007","article-title":"Lipopolysaccharide modification in Gram-negative bacteria during chronic infection","volume":"40","author":"Maldonado","year":"2016","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.cmi.2025.09.015_bib33","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1128\/AAC.00296-10","article-title":"Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa","volume":"54","author":"Moy\u00e1","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.09.015_bib34","volume":"68","author":"Le Terrier","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.09.015_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107081","article-title":"Activity of aztreonam\/avibactam and ceftzazidime\/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance","volume":"63","author":"Mushtaq","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.09.015_bib36","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/jac\/dkab496","article-title":"Comparative analysis of in vitro dynamics and mechanisms of ceftolozane\/tazobactam and imipenem\/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones","volume":"77","author":"Gomis-Font","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.09.015_bib37","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ijantimicag.2009.03.021","article-title":"Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates","volume":"34","author":"Livermore","year":"2009","journal-title":"Int J Antimicrob Agents"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25004653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25004653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:32:28Z","timestamp":1773919948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25004653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1198743X25004653"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.09.015","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complex pathways to ceftolozane-tazobactam resistance in clinical Pseudomonas aeruginosa isolates: a genomic epidemiology study","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}